{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:34:10Z","timestamp":1792708450022,"version":"4.5.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Locally advanced or metastatic urothelial carcinoma (la\/mUC) is associated with poor prognosis and limited treatment options. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach. While previous meta-analyses have shown the efficacy and safety of ADCs in UC, the rapid development of new ADC agents and combination therapies necessitates an updated and comprehensive evidence synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A comprehensive search was performed in PubMed, Embase, Cochrane Library, and Web of Science from inception to September 2025. Interested outcomes include overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AES). RoB 2.0, ROBINS-I tools and GRADE framework were used for quality assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 30 studies (5 RCTs and 25 single-arm trails), involving 3,631 patients, were included. Network meta-analysis showed that, compared with standard therapy, enfortumab vedotin (EV) in combination with pembrolizumab significantly improved OS (HR = 0.63, 95%CI: 0.43-0.92), ORR (OR = 3.33, 95% CI: 1.65-6.74), and PFS (HR = 0.48, 95% CI: 0.41-0.57). The safety results indicate that the ADC agents have a higher incidence rate of \u22653AES. The analysis of single-arm trails revealed that bulumtatug fuvedotin combined with toripalimab achieved an ORR as high as 88% (95% CI: 73%-96%), while disitamab vedotin-based combination therapy showed the longest median OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides a comprehensive synthesis of the latest clinical evidence on ADC-based monotherapy and combination regimens for la\/mUC. The findings confirm the compelling efficacy and manageable safety profile of ADCs in this setting, while also underscoring the need for further clinical trials to validate and refine personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD 420251114022.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1728521","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:31:36Z","timestamp":1774369896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Youran","family":"Dai","sequence":"first","affiliation":[{"name":"Department of Traditional Chinese Medicine, Beijing Shijitan Hospital affiliated to Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Xiao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Beijing Shijitan Hospital affiliated to Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Beijing Shijitan Hospital affiliated to Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Qihuang Chinese Medicine school, Beijing University of Chinese Medical","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Beijing Shijitan Hospital affiliated to Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.10.008","article-title":"Global burden of urologic cancers, 1990-2013","volume":"71","author":"Dy","year":"2017","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transd Targ Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20250008","article-title":"Contemporary management of metastatic urothelial carcinoma","volume":"66","author":"Oh","year":"2025","journal-title":"Investig Clin Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1789096","article-title":"Antibody-drug conjugates for the treatment of urothelial carcinoma","volume":"21","author":"Ravi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.20892\/j.issn.2095-3941.2025.0284","article-title":"Advances in antibody-drug conjugates for urothelial carcinoma treatment","volume":"22","author":"Wei","year":"2025","journal-title":"Cancer Biol Med."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1069356","article-title":"Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma","volume":"12","author":"Fenton","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1377924","article-title":"Efficacy and safety of antibody-drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials","volume":"15","author":"Ren","year":"2024","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1583654","article-title":"Efficacy and safety of antibody-drug conjugates in the treatment of advanced urological cancers: a systematic review and a meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"17588359251357527","DOI":"10.1177\/17588359251357527","article-title":"First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials","volume":"17","author":"Xie","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13080","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports","volume":"13","author":"Taylor","year":"2009","journal-title":"Health Technol Assess"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1622966","article-title":"Outcomes of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic cancer: systematic review and meta-analysis","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1397","article-title":"A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data","volume":"11","author":"Seide","year":"2020","journal-title":"Res Synth Methods"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.394","article-title":"EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1\/PD-L1 inhibitors","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2023.41.6_suppl.498","article-title":"BT8009-100: A phase I\/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced Malignancies associated with nectin-4 expression, including urothelial cancer (UC)","volume":"41","author":"Baldini","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"De Vries","year":"2023","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4567","article-title":"Phase 1\/2 Duravelo-1 study: Preliminary results of nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"43","author":"Giannatempo","year":"2025","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.7_suppl.770","article-title":"ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1\/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3\/2 genetic alterations (GAs)","volume":"44","author":"Jain","year":"2026","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4519","article-title":"9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-na\u00efve patients with locally advanced or metastatic urothelial carcinoma (la\/mUC): Results from a phase 1b\/2 study","volume":"43","author":"Jiang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70368","DOI":"10.1002\/cam4.70368","article-title":"Phase 2 trial of enfortumab vedotin in patients with previously treated locally advanced or metastatic urothelial carcinoma in China","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"114096","DOI":"10.1016\/j.ejca.2024.114096","article-title":"A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma","volume":"205","author":"Qu","year":"2024","journal-title":"Eur J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest New Drugs"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16572","article-title":"Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1\/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la\/mUC): An open-label, single-arm, phase II study","volume":"42","author":"Wahafu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s12885-025-14154-4","article-title":"RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100637","DOI":"10.1016\/j.medj.2025.100637","article-title":"Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study","volume":"6","author":"Yan","year":"2025","journal-title":"Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00345-025-05544-1","article-title":"Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma","volume":"43","author":"Yao","year":"2025","journal-title":"World J Urol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.796","article-title":"Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1\/2 MK-2870-001 study","volume":"43","author":"Ye","year":"2025","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2212201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.04.009","article-title":"Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study","volume":"36","author":"Zhang","year":"2025","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02362-0","article-title":"Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.annonc.2025.05.010","article-title":"Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis","volume":"36","author":"Hoffman-Censits","year":"2025","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/spcare-2024-004984","article-title":"Single-arm clinical trials: design, ethics, principles","volume":"15","author":"Wang","year":"2024","journal-title":"BMJ Supp Palliat Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0440","article-title":"Payload-binding fab fragments increase the therapeutic index of MMAE antibody-drug conjugates","volume":"22","author":"Bordeau","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1395127","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"104090","DOI":"10.1016\/j.critrevonc.2023.104090","article-title":"Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2","volume":"190","author":"Schlam","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody-drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.euf.2025.07.016","article-title":"The Future of Novel Antibody-Drug Conjugates in Localized Urothelial Cancer","volume":"12","author":"Filon","year":"2026","journal-title":"Eur Urol Focus"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/CMAR.S418009","article-title":"Current and emerging treatments for urothelial carcinoma: A focus on enfortumab vedotin","volume":"15","author":"Shafique","year":"2023","journal-title":"Cancer Manag Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8365","article-title":"High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2473695","article-title":"Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma","volume":"34","author":"Santoni","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.01.007","article-title":"Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: A phase 3 trial of enfortumab vedotin versus chemotherapy","volume":"85","author":"Rosenberg","year":"2024","journal-title":"Eur Urol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1624386","article-title":"Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31090422","article-title":"Canadian expert recommendations on safety overview and toxicity management strategies for sacituzumab govitecan based on use in metastatic triple-negative breast cancer","volume":"31","author":"Manna","year":"2024","journal-title":"Curr Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"16405","DOI":"10.1038\/s41598-025-01753-1","article-title":"Comprehensive metabolomics study identifies SN-38 organ specific toxicity in mice","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","first-page":"116318","DOI":"10.1016\/j.jpba.2024.116318","article-title":"Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate","volume":"248","author":"Fang","year":"2024","journal-title":"J Pharm BioMed Anal"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0743","article-title":"Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody-drug conjugate for treatment of nectin-4-expressing cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00262-024-03635-3","article-title":"Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells","volume":"73","author":"Rajasekaran","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbab017","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30750-2","article-title":"Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis","volume":"20","author":"Saad","year":"2019","journal-title":"Lancet Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1095_21","article-title":"Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis","volume":"18","author":"Yeh","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.653491","article-title":"The clinical significance and prognostic value of HER2 expression in bladder cancer: A meta-analysis and a bioinformatic analysis","volume":"11","author":"Gan","year":"2021","journal-title":"Front Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"B82","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12672-025-02457-8","article-title":"Progress of antibody-drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges","volume":"16","author":"Zeng","year":"2025","journal-title":"Discov Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"12929","DOI":"10.26355\/eurrev_202012_24196","article-title":"Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery","volume":"24","author":"Li","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Delivery"},{"key":"B85","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-023-01475-9","article-title":"Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium","volume":"16","author":"Yu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020258","article-title":"Understanding the toxicity profile of approved ADCs","volume":"17","author":"Ballest\u00edn","year":"2025","journal-title":"Pharmaceutics"},{"key":"B88","doi-asserted-by":"publisher","first-page":"17534666241299935","DOI":"10.1177\/17534666241299935","article-title":"Interstitial lung disease with antibody-drug conjugates: a real-world pharmacovigilance study based on the FAERS database during the period 2014-2023","volume":"18","author":"Shi","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"B89","doi-asserted-by":"publisher","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2479417","article-title":"Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates","volume":"21","author":"Park","year":"2025","journal-title":"Future Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3098","article-title":"Postmarketing safety of sacituzumab govitecan: A pharmacovigilance study based on the FDA adverse event reporting system","volume":"115","author":"Li","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.859892","article-title":"The applicability of the results in the asian population of ORIENT-11 to a western population according to the ICH-E5 framework","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3760\/cma.j.cn112152-20200421-00362","article-title":"Bladder cancer incidence, mortality and temporal trends in China","volume":"43","author":"Li","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1728521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:31:41Z","timestamp":1774369901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1728521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2026.1728521"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1728521","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"1728521"}}